Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATR | Q13535 | 11/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.42 |
| ▸ | RXRB | P28702 | 1/20 | 0.42 |
| ▸ | RXRG | P48443 | 1/20 | 0.42 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31211538 | 0.81 | RXRA (0.47) | ALDH1A1LMNAPOLBATRCYP4F2 | |
| SCHEMBL31358026 | 0.80 | ALDH1A1 (0.44) | ALDH1A1LMNAPOLBATRCYP4F2 | |
| SCHEMBL15666749 | 0.79 | CYP4F2 (0.42) | ALDH1A1LMNAPOLBATRCYP4F2 | |
| SCHEMBL30291997 | 0.79 | CYP4F2 (0.42) | ALDH1A1LMNAPOLBATRCYP4F2 | |
| SCHEMBL31058056 | 0.78 | ALDH1A1 (0.42) | ALDH1A1LMNAPOLBATRCYP4F2 | |
| SCHEMBL31750098 | 0.78 | ALDH1A1 (0.42) | ALDH1A1LMNAPOLBATRCYP4F2 | |
| SCHEMBL23458850 | 0.75 | ALDH1A1 (0.44) | ALDH1A1LMNAPOLBATRCYP4F2 | |
| SCHEMBL30828321 | 0.75 | ALDH1A1 (0.44) | ALDH1A1LMNAPOLBATRCYP4F2 | |
| SCHEMBL30301952 | 0.75 | CYP4F2 (0.46) | ALDH1A1LMNAPOLBATRCYP4F2 | |
| SCHEMBL29864329 | 0.75 | ALDH1A1 (0.44) | ALDH1A1LMNAPOLBATRCYP4F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134087-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2020-03-18 | — | — | EP | disclosed |
| US-9688698-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150307522-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307522-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, DRD4 | ALDH1A1 103/4885LMNA 4162/4885POLB 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.